Gross Profit Analysis: Comparing Amgen Inc. and Taro Pharmaceutical Industries Ltd.

Amgen's dominance over Taro in gross profit trends.

__timestampAmgen Inc.Taro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201415641000000580006000
Thursday, January 1, 201517435000000676585000
Friday, January 1, 201618829000000778966000
Sunday, January 1, 201718780000000671251000
Monday, January 1, 201819646000000463508000
Tuesday, January 1, 201919006000000445724000
Wednesday, January 1, 202019265000000399725000
Friday, January 1, 202119525000000296656000
Saturday, January 1, 202219917000000293122000
Sunday, January 1, 202319775000000268323000
Monday, January 1, 202420566000000304979000
Loading chart...

Unleashing insights

Gross Profit Trends: Amgen Inc. vs. Taro Pharmaceutical Industries Ltd.

In the competitive landscape of the pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of Amgen Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Amgen, a biotech giant, consistently outperformed Taro, with its gross profit peaking in 2022 at nearly $20 billion, marking a 27% increase from 2014. In contrast, Taro's gross profit showed a declining trend, dropping by over 50% from its 2016 peak to 2023. This stark contrast highlights Amgen's robust market position and strategic growth, while Taro faces challenges in maintaining its profitability. The data for 2024 is incomplete, indicating potential changes in the coming year. Investors and industry analysts should watch these trends closely as they reflect broader market dynamics and company-specific strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025